Trade Ideas April 16, 2026 12:27 PM

Exelixis: Play the Two-Backbone Setup — Cabometyx Cash Engine Plus Zanzalintinib Growth

A structured long trade that buys current stable cash flow and optionality from a newly approved oncology asset

By Avery Klein EXEL
Exelixis: Play the Two-Backbone Setup — Cabometyx Cash Engine Plus Zanzalintinib Growth
EXEL

Exelixis combines a durable cash-generating franchise in Cabometyx with a newly approved, potentially multi-indication next-generation asset, zanzalintinib. The balance sheet and cash flow profile give a margin of safety; positive regulatory and clinical catalysts could expand valuation. This trade idea lays out an entry, stop, and target with a rationale tied to fundamentals, valuation, and technicals.

Key Points

  • Exelixis combines a cash-generating Cabometyx franchise with zanzalintinib upside following FDA approval in mCRC.
  • Financials are solid: EPS ~$3.01, free cash flow ~$875.8M, cash ~$1.19B, and effectively no debt.
  • Valuation is mid-teen P/E with room for multiple expansion if pipeline catalysts convert to revenue.
  • Technicals are constructive (RSI ~54, MACD bullish) and short interest could amplify moves in either direction.

Hook & thesis

Exelixis offers a simple investment prism: steady cash flow from an established franchise plus high-upside optionality from zanzalintinib. Cabometyx has been the company’s commercial backbone; zanzalintinib, now FDA approved for metastatic colorectal cancer, is positioned to add meaningful revenue if later-stage trials expand indications. The combination means you are not buying pure binary biotech risk — you are buying a profitable oncology company with growth optionality.

That mix supports a structured long trade at today’s levels. With the shares trading around $44.14 and the company producing strong free cash flow, a conservative long against a defined stop makes sense for traders willing to ride data-driven moves over the coming months.

Why the market should care

Exelixis is a profitable oncology company that has been monetizing Cabometyx for years while reinvesting in R&D. The company’s financial profile is unusually robust for a biotech: reported EPS around $3.01 and a trailing P/E near 14.7 give the business an earnings base that supports the current market cap in the low $11 billion range (market cap roughly $11.5B, enterprise value roughly $11.02B).

Key balance-sheet and cash-flow points matter for the thesis. Exelixis reported free cash flow of about $875.8M and holds roughly $1.19B in cash on the balance sheet while showing effectively zero debt. Liquidity metrics are strong (current ratio ~3.56, quick ratio ~3.5), which means management can fund R&D and commercialization without near-term financing pressure. That matters because the market can disproportionately reward a profitable oncology company that also delivers new approvals.

Fundamentals & what to watch

Concrete numbers underpin the investment case:

  • Share price: $44.14 (current).
  • EPS: $3.01; trailing P/E roughly 14.7.
  • Free cash flow: $875.8M; cash on hand roughly $1.19B; no recorded debt.
  • Valuation multiples: price-to-sales ~4.96, EV/EBITDA ~11.95, price-to-free-cash-flow ~13.13.

These numbers show a company that already generates meaningful cash and earnings. That lets investors play upside from zanzalintinib without buying a company that needs to raise capital to survive. Zanzalintinib’s FDA approval for metastatic colorectal cancer (mCRC) is a real commercial inflection point: initial U.S. approval narrows the binary regulatory risk and shifts focus to uptake, label expansion, and combination trials.

Valuation framing

At a market capitalization near $11.5B and trading at a P/E in the mid-teens, Exelixis sits between pure growth biotech and mature pharma. The multiples imply the market is valuing the current Cabometyx cash flow and giving partial credit for pipeline upside. Price-to-sales near 5 is relatively rich versus cyclic biotech averages, but the combination of profitability (EPS $3.01), strong free cash flow, and a debt-free balance sheet justifies a premium.

Compare this to the company’s own technical momentum: the 50-day SMA is around $42.97 and the 20-day SMA near $43.30 — both below the current price, which supports the thesis that the market is comfortable with current fundamentals. Momentum indicators are neutral-to-positive: RSI about 53.9 and MACD showing bullish momentum (MACD line above signal line), indicating the stock is not extended and has room to run if catalysts materialize.

Catalysts

  • Commercial rollout and uptake of zanzalintinib in mCRC following FDA approval (regulatory milestone realized on 02/28/2026) - commercialization metrics and early uptake data will drive sentiment.
  • Phase 3 readouts in other tumor types where zanzalintinib is being evaluated - positive results would materially expand the addressable market.
  • Partnerships or label-expansion deals - strategic collaborations could accelerate reach and reduce commercialization risk.
  • Hedge against competition or pricing shifts in renal cell carcinoma - Cabometyx performance versus competitive regimens matters for near-term revenue.

Technical and market microstructure signals

Technicals are constructive without being euphoric. The 10-day SMA is $44.50, the 9-day EMA sits near $44.36, and the 50-day EMA is around $43.17, creating a bullish confluence. Short interest data show around 27.26M shares short as of 03/31/2026 with days-to-cover near 11 on that snapshot. Recent short-volume data show large short participation in daily volume, which raises the possibility of squeezes into positive catalysts; conversely, it can amplify downside on negative headlines.

Trade plan (actionable)

Summary: Enter a defined long at $44.14 with a stop at $38.00 and a primary target at $52.00. This trade is intended to be held as a long-term catalyst trade to give new approvals and trial readouts time to convert into commercial traction.

Trade Detail
Entry price $44.14
Stop loss $38.00
Target price $52.00
Time horizon Long term (180 trading days) - Give commercial uptake and Phase 3 readouts time to evolve.
Risk level Medium - company is profitable but drug commercialization and trial risk remain.

Why these levels? Entry at $44.14 buys the current market price where fundamentals (EPS, cash flow) and technicals align. The $38 stop protects capital below the 50-day SMA and below a plausible stress level should uptake stall or commercial data disappoint. The $52 target is ambitious but reachable: it sits above the prior 52-week high ($49.62), reflecting multiple expansion as zanzalintinib traction compounds and Cabometyx revenues remain stable.

Risks and counterarguments

No investment in oncology is risk-free. Key risks:

  • Commercial uptake risk: FDA approval removes a regulatory binary, but physician adoption, payer coverage, and competitive dynamics will determine commercial revenue. Slow uptake would pressure shares.
  • Clinical risk in additional indications: Zanzalintinib is in several Phase 3 programs; failures or negative safety signals in other tumor types could meaningfully reduce the drug’s upside.
  • Pricing and reimbursement pressure: Oncology pricing scrutiny and payer formulary decisions could limit realized pricing versus assumptions, squeezing margins and free cash flow.
  • Competitive landscape: Rival combinations and new approvals in renal cell carcinoma and colorectal cancer (e.g., Merck/Eisai combos reporting strong data) can take share or force Exelixis into less favorable commercial positions.
  • Market sentiment and technical risk: High short interest and heavy short-volume participation can amplify pullbacks; a broader biotech sell-off could drown out company-specific positives.

Counterargument: A skeptical view is that the market has already priced in most of zanzalintinib’s upside and that Cabometyx faces incremental competitive pressure that could cap growth. If zanzalintinib fails to deliver label expansions or meaningful uptake beyond a narrow mCRC niche, the stock could revert to a multiple more typical of a mature single-product oncology company.

What would change my mind

I would downgrade the trade if: 1) early commercial metrics for zanzalintinib show poor adoption or significant safety/tolerability concerns; 2) a Phase 3 readout in a major indication fails; or 3) management signals material downward revisions to revenue guidance for Cabometyx. Conversely, I would add to the position if Exelixis posts accelerating commercial sales for zanzalintinib, produces positive Phase 3 readouts in additional indications, or announces partnerships that materially de-risk commercialization.

Conclusion

This is a pragmatic long with a clear downside guard. You are buying a profitable oncology operator trading at a reasonable multiple with free cash flow near $875.8M and no debt, while also owning optionality from a recently approved drug. The trade balances income-like characteristics with binary upside and is appropriate for investors who want to back real commercial traction rather than an early-stage biotechnology binary bet. Position size should reflect the medium-level risk profile: keep the stop in place and reassess after initial commercial metrics and next wave Phase 3 readouts.


Trade plan recap: Buy $44.14, stop $38.00, target $52.00, holding period: long term (180 trading days).

Risks

  • Slow commercial uptake or poor payer coverage for zanzalintinib could limit revenue upside.
  • Negative Phase 3 readouts in other indications would materially reduce the drug’s addressable market.
  • Competitive pressure and pricing scrutiny in oncology could compress margins and growth.
  • High short interest and heavy short-volume participation increase volatility and downside risk.

More from Trade Ideas

Buy CLMB: Play the Channel Consolidation Tailwind After Recent Deals and Partnerships Apr 16, 2026 Adagene: ADG126 Momentum and Partner Deals Support a Mid-Term Long Trade Apr 16, 2026 Abbott at a Rare Discount: Dividend Growth King Hits 52-Week Low Apr 16, 2026 Riot Platforms: Upgrade to Buy as Leadership Shift Meets a Path to Re-rate Apr 16, 2026 Chart Industries: Merger Arbitrage on 'Blue Gold' Exposure — Takeout Nears, But Structural Upside Exists Apr 16, 2026